Mary Kay Fenton - 01 Feb 2022 Form 4 Insider Report for Talaris Therapeutics, Inc. (TRML)

Role: Chief Financial Officer
Signature: /s/ Mary Kay Fenton
Issuer symbol: TRML
Transactions as of: 01 Feb 2022
Net transactions value: +$13,000
Form type: 4
Filing time: 02 Feb 2022, 17:00:57 UTC
Previous filing: 17 Jun 2021
Next filing: 24 Jun 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	TALS	Common Stock	Award	$13,000	+1,000		$13.00	1,000	31 Dec 2021	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	TALS	Stock Option (Right to Buy)	Award	$0	+200,000		$0.000000	200,000	01 Feb 2022	Common Stock	200,000	$9.10	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	These shares were acquired by the reporting individual under the issuer's 2021 Employee Stock Purchase Plan ("ESPP") in a transaction exempt under Rule 16b-3(c).
F2	The shares underlying this option shall vest as follows: 25% shall vest on February 1, 2023; and the remaining shall vest in 36 equal monthly installments thereafter.